HBV reactivation after start of bulevirtide mono-treatment for a HBV/HDV coinfected patient: a case report

Background Bulevirtide is the first in-label treatment option for HBV/HDV coinfection in combination with nucleos(t)ide (NA) analogues or as monotherapy. We report a case of a patient with hepatitis B reactivation after start of bulevirtide monotreatment, which resulted in the need for a NA-start.